• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/10/21 11:57:25 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $USNA alert in real time by email
    SC 13G/A 1 tv02071-usanahealthsciencesi.htm SCHEDULE 13G/A usanahealthsciencesinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 2)*

    Name of issuer:  USANA Health Sciences Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  90328M107

    Date of Event Which Requires Filing of this Statement: December 31, 2020

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  90328M107

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    27,422

    7.  SOLE DISPOSITIVE POWER

    1,390,983

    8.  SHARED DISPOSITIVE POWER

    36,677

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,427,660

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.79%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    USANA Health Sciences Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    3838 West Parkway Blvd.
    Salt Lake City, Utah 84120

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    90328M107

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

    1,427,660

      (b) Percent of Class:

    6.79%

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  0

    (ii)  shared power to vote or direct to vote:  27,422

    (iii)  sole power to dispose of or to direct the disposition of:  1,390,983

    (iv)  shared power to dispose or to direct the disposition of:  36,677

    Comments:

     

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    Not applicable

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    See Attached Appendix A

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 8, 2021

    By /s/ Christine M. Buchanan
    Name: Christine M. Buchanan
    Title:  Principal

     

     

    Appendix A

    Subsidiary:

    Vanguard Asset Management, Limited

    Vanguard Fiduciary Trust Company

    Vanguard Global Advisors, LLC

    Vanguard Group (Ireland) Limited

    Vanguard Investments Australia Ltd

    Vanguard Investments Canada Inc.

    Vanguard Investments Hong Kong Limited

    Vanguard Investments UK, Limited

    *Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G

     

    Get the next $USNA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $USNA

    DatePrice TargetRatingAnalyst
    6/23/2023Buy
    Sidoti
    7/7/2022$78.00 → $53.00Hold → Underperform
    Jefferies
    4/14/2022$86.00Neutral
    DA Davidson
    More analyst ratings

    $USNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    USANA's Kevin Guest Shares 7 Daily Habits for Lasting Health, Harmony for National Wellness Month

    SALT LAKE CITY, Aug. 4, 2025 /PRNewswire/ -- With August marking National Wellness Month, Kevin Guest, Executive Chairman of USANA Health Sciences (NYSE:USNA), is encouraging people to embrace small daily habits that lead to lasting wellness mentally, physically, and emotionally. "Wellness isn't something you check off a list; it's a rhythm you live," said Guest, author of All the Right Reasons: 12 Timeless Principles for Living a Life in Harmony. "You don't have to overhaul your life. But if you shift a few daily choices, you'll be amazed by how much calmer, clearer, and more

    8/4/25 7:07:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Health Sciences Reports Second Quarter 2025 Results and Reiterates Full-Year Outlook

    USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal second quarter ended June 28, 2025. Key Financial Results Second Quarter 2025 vs. Second Quarter 2024 Net sales of $236 million versus $213 million, representing 11% year-over-year growth. Net earnings of $9.7 million versus $10.4 million. Diluted EPS of $0.52 as compared with $0.54. Adjusted diluted EPS(1) of $0.74 as compared with $0.54. Adjusted EBITDA(2) of $30 million versus $27 million. Direct selling Active Customers of 418,000 versus 468,000. Hiya Active Monthly Subscribers of 200,400. Company reiterates fiscal year 2025 outlook. Q2 2025 Financial Performance C

    7/22/25 4:05:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Schedules Second Quarter 2025 Earnings Release and Conference Call

    USANA Health Sciences, Inc. (NYSE:USNA) today announced that second quarter 2025 results will be released after the close of market on Tuesday, July 22, 2025. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, July 23, 2025 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures

    7/2/25 4:05:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fuller Gilbert A sold $30,789 worth of shares (1,058 units at $29.10), closing all direct ownership in the company (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    8/8/25 2:22:21 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    CHIEF SALES OFFICER Mulham David Mulham sold $106,364 worth of shares (3,515 units at $30.26), decreasing direct ownership by 28% to 9,260 units (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    7/31/25 11:03:26 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    CHIEF SCIENTIFIC OFFICER Armstrong Kathryn Michelle converted options into 1,165 shares and covered exercise/tax liability with 517 shares (SEC Form 4)

    4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

    7/28/25 1:22:54 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    SEC Filings

    View All

    SEC Form 10-Q filed by USANA Health Sciences Inc.

    10-Q - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    8/5/25 4:50:15 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by USANA Health Sciences Inc.

    SCHEDULE 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    7/29/25 2:50:55 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Health Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - USANA HEALTH SCIENCES INC (0000896264) (Filer)

    7/22/25 4:06:41 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sidoti initiated coverage on USANA

    Sidoti initiated coverage of USANA with a rating of Buy

    6/23/23 9:12:38 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA downgraded by Jefferies with a new price target

    Jefferies downgraded USANA from Hold to Underperform and set a new price target of $53.00 from $78.00 previously

    7/7/22 9:35:48 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    DA Davidson initiated coverage on USANA with a new price target

    DA Davidson initiated coverage of USANA with a rating of Neutral and set a new price target of $86.00

    4/14/22 7:45:27 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Leadership Updates

    Live Leadership Updates

    View All

    USANA Exec. Chairman Kevin Guest Celebrates Guitar Month, Stress Awareness Month for Harmony

    SALT LAKE CITY, April 1, 2025 /PRNewswire/ -- USANA Health Sciences (NYSE:USNA) Executive Chairman Kevin Guest marks April's convergence of International Guitar Month and Stress Awareness Month, as a perfect pairing that celebrates the healing power of music for mental well-being. While music has long been heralded as a universal remedy, the guitar offers far more than just melodies. Studies, stories and specialists alike agree: playing the guitar is a proven method to reduce stress. A passionate, performing guitarist himself, Guest invites others to join the cause. "Music has

    4/1/25 7:47:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Appoints New Chief Scientific Officer

    Dr. Kathryn Armstrong brings 17 years of scientific expertise to the company SALT LAKE CITY, Jan. 22, 2025 /PRNewswire/ -- USANA Health Sciences, Inc., a global leader in cellular nutrition, is proud to announce that Dr. Kathryn Armstrong, Ph.D., will be assuming the role of chief scientific officer at the company. Kathryn has served as USANA's executive vice president of research and development since July of 2024.  Kathryn's predecessor, Dr. Rob Sinnott, announced his retirement at the end of 2024, but will continue to assist in the company's pursuit for scientific excellence as its senior scientific fellow.

    1/22/25 7:07:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Executive Chairman Kevin Guest Encourages Connections with July's "Social Wellness Month"

    SALT LAKE CITY, July 1, 2024 /PRNewswire/ -- Throughout July, Kevin Guest, executive chairman at USANA Health Sciences (NYSE:USNA), is emphasizing boosting social connections during "Social Wellness Month." Social wellness—the ability to form meaningful relationships and interact positively with others—not only enhances our emotional well-being but also significantly impacts our overall health. "Strong social connections reduce stress, improve mental health, and even extend life expectancy," said Guest. "In a world where digital interactions often replace face-to-face communic

    7/1/24 7:13:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/13/24 10:49:58 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/13/23 11:26:45 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by USANA Health Sciences Inc. (Amendment)

    SC 13G/A - USANA HEALTH SCIENCES INC (0000896264) (Subject)

    2/11/22 3:48:24 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $USNA
    Financials

    Live finance-specific insights

    View All

    USANA Health Sciences Reports Second Quarter 2025 Results and Reiterates Full-Year Outlook

    USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal second quarter ended June 28, 2025. Key Financial Results Second Quarter 2025 vs. Second Quarter 2024 Net sales of $236 million versus $213 million, representing 11% year-over-year growth. Net earnings of $9.7 million versus $10.4 million. Diluted EPS of $0.52 as compared with $0.54. Adjusted diluted EPS(1) of $0.74 as compared with $0.54. Adjusted EBITDA(2) of $30 million versus $27 million. Direct selling Active Customers of 418,000 versus 468,000. Hiya Active Monthly Subscribers of 200,400. Company reiterates fiscal year 2025 outlook. Q2 2025 Financial Performance C

    7/22/25 4:05:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Schedules Second Quarter 2025 Earnings Release and Conference Call

    USANA Health Sciences, Inc. (NYSE:USNA) today announced that second quarter 2025 results will be released after the close of market on Tuesday, July 22, 2025. Shortly following the issuance of the Company's earnings release, the Company will post its Management Commentary document on the Company's Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, July 23, 2025 at 11:00 a.m. Eastern Time. The call will be broadcast over the Internet and can be accessed at http://ir.usana.com. About USANA USANA develops and manufactures

    7/2/25 4:05:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    USANA Health Sciences Reports First Quarter 2025 Results and Reiterates Full-Year Outlook

    USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal first quarter ended March 29, 2025. Key Financial Results First Quarter 2025 vs. First Quarter 2024 Net sales of $250 million versus $228 million, representing year-over-year growth of 10% and 12% in constant currency. Net earnings of $9.4 million versus $16.5 million. Diluted EPS of $0.49 as compared with $0.86. Adjusted diluted EPS(1) of $0.73 as compared with $0.86. Adjusted EBITDA(2) of $30 million versus $33 million. Direct selling Active Customers of 459,000 versus 494,000. Hiya Active Monthly Subscribers of 224,000. Company reiterates fiscal year 2025 outlook. Q1 2025 Financia

    4/22/25 4:05:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care